Association of Survival with Femoropopliteal Artery Revascularization with Drug-Coated Devices

Eric A. Secemsky, Harun Kundi, Ido Weinberg, Michael R. Jaff, Anna Krawisz, Sahil A. Parikh, Joshua A. Beckman, Jihad Mustapha, Kenneth Rosenfield, Robert W. Yeh

Research output: Contribution to journalArticlepeer-review

157 Scopus citations


Importance: In a recent meta-analysis of randomized clinical trials, femoropopliteal artery revascularization with paclitaxel drug-coated devices was associated with increased long-term all-cause mortality compared with non-drug-coated devices. However, to our knowledge, these findings have not been replicated in other data sources and may be subject to confounding from missing data associated with patient withdrawal and loss to follow-up. Objective: To evaluate differences in all-cause mortality between patients who were treated with drug-coated devices vs non-drug-coated devices for femoropopliteal artery revascularization. Design, Setting, and Participants: This nationwide, multicenter retrospective cohort study included 16560 Centers for Medicare and Medicaid Services beneficiaries who were admitted for femoropopliteal artery revascularization from January 1, 2016, to December 31, 2016. All-cause mortality was analyzed through September 30, 2017. Exposures: Drug-coated devices (drug-eluting stent [DES] or drug-coated balloon [DCB]) compared with non-drug-coated devices (bare metal stent or uncoated percutaneous transluminal angioplasty balloon). Main Outcomes and Measures: The primary outcome was all-cause mortality analyzed through the end of follow-up. Results: Among 16560 patients treated at 1883 hospitals, the mean (SD) age was 72.9 (11) years, 7734 (46.7%) were men, 12232 (73.9%) were white, 8222 (49.7%) currently or had previously used tobacco, 9817 (59.3%) had diabetes, and 8450 (51.0%) had critical limb ischemia (CLI). Drug-coated devices were used in 5989 participants (36.2%). The median follow-up was 389 days (interquartile range, 277-508 days). Among all patients, treatment with drug-coated devices was associated with a lower cumulative incidence of all-cause mortality compared with treatment with non-drug-coated devices through 600 days postprocedure (32.5% vs 34.3%, respectively; log-rank P =.007). Similar survival trends were observed when treatment was stratified by using a DCB alone or DES with or without DCB. After multivariable adjustment, drug-coated devices were not associated with a difference in all-cause mortality compared with non-drug-coated devices (hazard ratio [HR], 0.97; 95% CI, 0.91-1.04; P =.43). These findings were consistent among those with CLI (HR, 0.93; 95% CI, 0.85-1.01; P =.09) or without CLI (HR, 0.94; 95% CI, 0.85-1.03; P =.20), and for those treated with DCB alone (HR, 0.94; 95% CI, 0.86-1.03; P =.17) or DES with or without DCB (HR, 0.97; 95% CI, 0.89-1.06; P =.48). Conclusions and Relevance: In this large nationwide analysis of Centers for Medicare and Medicaid Services beneficiaries, there was no evidence of increased all-cause mortality following femoropopliteal artery revascularization with drug-coated devices compared with non-drug-coated devices.

Original languageEnglish (US)
Pages (from-to)332-340
Number of pages9
JournalJAMA Cardiology
Issue number4
StatePublished - Apr 2019
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Association of Survival with Femoropopliteal Artery Revascularization with Drug-Coated Devices'. Together they form a unique fingerprint.

Cite this